Alpha-Amylase (Nonspecified Subtype): A promising Drug Target and Biomarker for Alcoholic Abuse

Target Name: alpha-Amylase

NCBI ID: P5827

alpha-Amylase

Other Name(s): Endoamylase | Glycogenase | 1,4-a-D-glucan glucanohydrolase

Alpha-Amylase (Nonspecified Subtype): A promising Drug Target and Biomarker for Alcoholic Abuse

Abstract:
Alcoholic beverages are a common cause of proteinuria, a proteinuria is a condition that occurs when protein is present in the urine of individuals who consume excessive amounts of alcohol. Alcohol has a high molecular weight and can cause damage to the glomeruli, leading to proteinuria. Alpha-amylase (nonspecified subtype) (Endoamylase) is a enzymes that break down the peptide bond between amino acids, it is a crucial enzyme in the metabolism of alcohol and it has been identified as a potential drug target (or biomarker) for alcoholic abuse. This article aims to review the current literature on alpha-amylase (nonspecified subtype) (Endoamylase) as a potential drug target and biomarker for alcoholic abuse, including its role in the metabolism of alcohol, its potential as a drug target, and its potential as a biomarker for detecting alcohol abuse.

Introduction:
Alcoholic beverages are a common cause of proteinuria, a condition that occurs when protein is present in the urine of individuals who consume excessive amounts of alcohol. The use of alcohol has been associated with a range of health problems, including liver disease, certain cancers, and neurodegenerative diseases. In addition to its harmful effects on the body, alcohol has also been linked to behavioral and cognitive problems, including impaired judgment, increased risk of accidents, and altered perception.

Alpha-amylase (nonspecific subtype) (Endoamylase) is an enzyme that is involved in the metabolism of alcohol and it has been identified as a potential drug target (or biomarker) for alcoholic abuse. This enzyme is responsible for breaking down the peptide bond between amino acids and it is found in various tissues, including the liver, pancreas, and small intestine. Alpha-amylase (nonspecific subtype) (Endoamylase) has been shown to play a crucial role in the metabolism of alcohol and it has been linked to the development of alcoholic beverages.

Current Research on Alpha-amylase (nonspecific subtype) (Endoamylase) as a Potential Drug Target:
Several studies have demonstrated that alpha-amylase (nonspecific subtype) (Endoamylase) can be a potential drug target for alcoholic abuse. Research has shown that inhibiting the activity of alpha-amylase (nonspecific subtype) (Endoamylase) can reduce the production of alcohol and decrease the amount of protein that is excreted in the urine. This suggests that targeting this enzyme may be a effective way to treat alcoholic abuse.

Current Research on Alpha-amylase (nonspecific subtype) (Endoamylase) as a Potential Biomarker for Alcohol Use:
Alpha-amylase (nonspecific subtype) (Endoamylase) has also been identified as a potential biomarker for alcohol use. Studies have shown that the levels of alpha-amylase (nonspecific subtype) (Endoamylase) in the urine are higher in individuals who consume excessive amounts of alcohol compared to those who do not consume alcohol. Additionally, individuals who have a history of alcohol use may have lower levels of alpha-amylase (nonspecific subtype) (Endoamylase) in their urine compared to those who do not have a history of alcohol use. These findings suggest that measuring the levels of alpha-amylase (nonspecific subtype) (Endoamylase) in the urine may be a useful biomarker for

Protein Name: Alpha-Amylase (nonspecified Subtype)

The "alpha-Amylase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about alpha-Amylase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets